This article explains, in educational terms, percutaneous thermal ablation — how the technology works and where it fits. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team.
Percutaneous Thermal Ablation Electrodes
Percutaneous thermal ablation relies on an applicator advanced through the skin to the tumor under imaging, so that energy is confined as much as possible to the target while sparing adjacent structures. Electrode and antenna design, including cooling features and active-tip geometry, is intended to shape the resulting ablation zone and manage temperature at the applicator interface. INVAMED's generator-based platforms, including the Peta RFA System and ThermoEdge RFA Platform, are built to drive such applicators across several soft-tissue applications. Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator.
Design and Technical Notes
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use. Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
Key Considerations
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Frequently Asked Questions
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005. INVAMED operates a dedicated R&D center (INVAcenter) focused on minimally invasive device development.
Clinical and Technical Context
MWA is frequently discussed for liver and lung tumors, but suitability, applicator selection, and power protocol are determined case by case by the interventional physician. INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. INVAMED's Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors is positioned specifically for intraosseous RF delivery in vertebral and spinal tumor ablation.
Related on INVAMED
- Oncology Ablation — product category
- HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment — Technical Overview
- What is the success rate of liver tumor ablation?
- ThermoEdge RFA Platform — Technical Overview
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.